Orchestra BioMed Holdings Inc. (OBIO) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Orchestra BioMed Holdings Inc. stock $4.14, price $7.12, that is 41.9% below the price, quality 41 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Orchestra BioMed Holdings Inc.
OBIO · USFar too expensive (fair value 42% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.
How to read this chart
60‑month range $2.35 – $22.18 · fair‑value band $3.11 – $5.18 · the $7.12 price screens above the $4.14 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.
Every Wednesday you see whether Orchestra BioMed Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States.
Show moreShow less
The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease.
It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure.
In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures.
It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral vascular disease.
Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.
Stock analysis
Orchestra BioMed Holdings Inc. (OBIO) currently trades at $7.12, while our estimate is $4.14, 42% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $3.11 (bear) to $5.18 (bull), the price of $7.12 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Orchestra BioMed Holdings Inc. reported revenue of $33.5M in FY2025 versus −$782K in FY2021. Reported net income was −$52.7M in FY2025.
Key figures
Market cap $454M Small · P/S ratio 15.5 · EPS (TTM) $−0.7600 · Return on equity −182% · Return on assets (EBIT) −75.8% (5-year average) · Operating margin −195% · Revenue (TTM) $31.2M · Revenue growth (YoY) −89.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).
What moves the price
The share trades about 2% below its 52-week high and 104% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −42%, OBIO screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, 6 officers or directors bought shares worth $310,204, most recently on Nov 9, 2026. Over the same period, one person sold shares worth $439,050. Buying cluster
- BuyRTW INVESTMENTS, LP10% owner1,200,000 shares at $5.00$6.0MNov 9, 2026
- BuyAndrew Lawrence TaylorChief Financial Officer1,000 shares at $5.00$5,000Nov 9, 2026
- BuyDavid P HochmanOfficer, Director5× since Mar 13, 2026: 35,000 shares, avg. $4.39$153,800Nov 9, 2026
- BuyDavid PacittiDirector20,000 shares at $5.00$100,000Nov 9, 2026
- BuyEric S FainDirector2× since May 14, 2026: 40,000 shares, avg. $4.57$182,600Nov 9, 2026
- SaleDarren ShermanOfficer, Director6× since Jun 1, 2026: 90,000 shares, avg. $4.88$439,050Nov 2, 202610b5-1 plan
- BuyDarren ShermanOfficer, Director2,000 shares at $5.33$10,660Aug 26, 2026
- BuyJason AryehDirector2× since May 15, 2026: 9,636 shares, avg. $3.89$37,481May 18, 2026
- SaleRTW INVESTMENTS, LP10% owner32 shares at $4.13$132Apr 27, 2026
Plus 17 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Compare Orchestra BioMed Holdings Inc. with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Return on equity by industry
- Quality Score by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs OBIO |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs OBIO |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs OBIO |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs OBIO |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs OBIO |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs OBIO |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs OBIO |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs OBIO |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs OBIO |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs OBIO |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Orchestra BioMed Holdings Inc. (OBIO) overvalued or undervalued?
What is the fair value of OBIO?
What is the quality score of OBIO?
What is the price target for Orchestra BioMed Holdings Inc. (OBIO)?
What is the Orchestra BioMed Holdings Inc. stock forecast for 2026?
What is the revenue of Orchestra BioMed Holdings Inc. (OBIO)?
What is the intrinsic value of Orchestra BioMed Holdings Inc. (OBIO)?
Is Orchestra BioMed Holdings Inc. stock overvalued or undervalued in 2026?
Is fair value the same as the market price of OBIO?
How much is Orchestra BioMed Holdings Inc. worth?
What do the bullish and bearish scenarios say about OBIO?
How solid is the balance sheet of Orchestra BioMed Holdings Inc. (OBIO)?
How far is OBIO from its 52-week high?
Which stocks are comparable to Orchestra BioMed Holdings Inc.?
Is Orchestra BioMed Holdings Inc. stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Orchestra BioMed Holdings Inc. (OBIO)?
What should I pay attention to with Orchestra BioMed Holdings Inc. right now?
Key figures of Orchestra BioMed Holdings Inc.
How large is the market capitalisation of Orchestra BioMed Holdings Inc. (OBIO)?
What is the P/S ratio of Orchestra BioMed Holdings Inc. (OBIO)?
What are the earnings per share of Orchestra BioMed Holdings Inc. (OBIO)?
What is the return on equity of Orchestra BioMed Holdings Inc. (OBIO)?
What is the EBIT return on assets of Orchestra BioMed Holdings Inc. (OBIO)?
What is the operating margin of Orchestra BioMed Holdings Inc. (OBIO)?
How fast is revenue growing at Orchestra BioMed Holdings Inc. (OBIO)?
How much free cash flow does Orchestra BioMed Holdings Inc. (OBIO) generate?
How much net cash does Orchestra BioMed Holdings Inc. (OBIO) hold?
Watch Orchestra BioMed Holdings Inc. in the live analysis
One click puts Orchestra BioMed Holdings Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.